journal
MENU ▼
Read by QxMD icon Read
search

Clinical Neuropharmacology

journal
https://www.readbyqxmd.com/read/29787393/recanalization-of-chronic-occlusion-of-the-middle-cerebral-artery-with-tissue-plasminogen-activator-treatment-a-case-report
#1
Seung Jae Lee, Jin Sung Cheong, Han Uk Ryu, Hyun Goo Kang
OBJECTIVES: Patients with chronic proximal middle cerebral artery (MCA) occlusion do not present with severe symptoms, but early recanalization of acute occlusion is associated with high morbidity and mortality. Tissue plasminogen activator (tPA) is a recombinant thrombolytic agent approved for treating ischemic stroke, although only a few cases of tPA administration in chronic MCA occlusion have yielded positive results. METHODS: A 71-year-old patient had a history of right MCA territorial infarction with the occlusion occurring 12 years ago (November 2005)...
May 21, 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29672326/long-term-outcome-of-adenosine-a2a-receptor-antagonist-on-lower-urinary-tract-symptoms-in-male-parkinson-disease-patients
#2
Takeya Kitta, Ichiro Yabe, Yukiko Kanno, Madoka Higuchi, Mifuka Ouchi, Mio Togo, Kimihiko Moriya, Ikuko Takahashi, Masaaki Matsushima, Hidenao Sasaki, Nobuo Shinohara
OBJECTIVES: In addition to motor symptoms, bladder dysfunction is a major clinical issue in patients with Parkinson disease (PD). Istradefylline is adenosine A2A receptor antagonist approved for PD patients with wearing-off symptoms. The aim of this study was to determine the long-term effects of istradefylline on lower urinary tract symptoms (LUTSs) in PD patients. METHODS: We enrolled 14 male PD patients. The mean age of patients was 73 years (61-77 years), the Hoehn-Yahr stage was 2 (2-3), and disease duration was 9 years (3-28 years)...
April 18, 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29634584/trazodone-and-parkinsonism-the-link-strengthens
#3
Aliya Iftikhar Sarwar
Trazodone, the most sedating atypical antidepressant, is widely used as an off-label hypnotic especially in the elderly. Although generally considered safe, it can potentially inhibit midbrain dopaminergic neurotransmission leading to the emergence of extrapyramidal adverse effects. Two previous cases of trazodone-induced parkinsonism have been described after its prolonged use as an antidepressant; however, there is no published case of secondary parkinsonism caused by trazodone in a nondepressed person after its use as a hypnotic...
April 9, 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29634583/restless-genital-syndrome-induced-by-milnacipran
#4
Keita Miyake, Manabu Takaki, Shinji Sakamoto, Kiyohiro Kawada, Shinichiro Inoue, Norihito Yamada
OBJECTIVES: Restless genital syndrome (RGS) includes discomfort, pain, numbness, vibration, restlessness, or a burning sensation involving the vagina, perineum, pelvis, penis, and proximal portion of the lower limbs in patients. The RGS has been sometimes reported in Parkinson disease. In patients without Parkinson disease, RGS is also known as persistent genital arousal disorder (PSAS), which includes uncontrollable genital arousal, with or without orgasm or genital engorgement, unrelated to sexual desire...
April 9, 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29596118/treatment-of-depression-with-duloxetine-in-mitochondrial-encephalopathy-lactic-acidosis-and-stroke-like-episodes
#5
Brittany Cozart, Jesus Diaz Vera, James D Denham, William L Whiting
The mitochondrial cytopathies are a heterogeneous group of diseases characterized by heteroplasmic maternal transmission and selective dysfunction of tissues and organs highly dependent on aerobic respiration (eg, skeletal muscle, cardiac muscle, and brain). Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) is a specific subtype of mitochondrial cytopathy that is commonly associated with mood disturbances in individuals who survive until adulthood. Because of the altered cellular metabolism inherent in MELAS, it is often difficult to determine drug dosing, drug choice, and treatment response in patients with this rare disease...
March 28, 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29746282/comparing-the-effects-of-atorvastatin-with-sodium-valproate-divalproex-on-frequency-and-intensity-of-frequent-migraine-headaches-a-double-blind-randomized-controlled-study
#6
Omid Hesami, Mohammad Sistanizad, Elnaz Asadollahzade, Mohammad-Sadegh Johari, Nahid Beladi-Moghadam, Homa Mazhabdar-Ghashghai
OBJECTIVES: To evaluate the prophylactic effects of atorvastatin on frequency, intensity, and duration of migraine attacks compared with sodium valproate. METHODS: In this randomized, double-blind, single-center controlled trial, patients with 6 to 15 migraine attacks per month, which were candidates of preventive treatment, were recruited. The patients were randomly allocated into 2 groups. The first group (A) received atorvastatin 40 mg daily, and the second group (B) received sodium valproate 500 mg daily...
May 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29537978/a-randomized-trial-of-oral-and-transdermal-rivastigmine-for-postural-instability-in-parkinson-disease-dementia
#7
Jaime McDonald, Emmanuelle Pourcher, Alexandra Nadeau, Philippe Corbeil
OBJECTIVES: The objective of this study was to compare the efficacy and safety of oral and transdermal rivastigmine for postural instability in patients with Parkinson disease dementia (PDD) who were candidates for a cholinesterase inhibitor. The primary outcome was the change in mean velocity of the center of pressure (CoP) after 6 months. Secondary outcomes included structural parameters of dynamic posturography, clinical rating scales, and adverse events requiring dose reduction. METHODS: Patients with PDD were randomized in a 1:1 ratio to oral or transdermal rivastigmine with target doses of 6 mg twice daily and 9...
May 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29533364/atomoxetine-in-the-treatment-of-adolescent-with-trichotillomania-and-attention-deficit-hyperactivity-disorder
#8
Serhat Türkoğlu, Fatih Hilmi Çetin
No abstract text is available yet for this article.
March 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29533363/treatment-of-intermittent-explosive-disorder-with-carbamazepine
#9
Fatma Coskun, Omer Faruk Akca
No abstract text is available yet for this article.
March 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29533362/antipsychotic-induced-pisa-syndrome-a-2-year-follow-up-study
#10
Yen-Feng Lee
OBJECTIVES: Pisa syndrome is characterized by lateral trunk flexion. It is an uncommon adverse drug reaction in patients on antipsychotic medication. Although Pisa syndrome has been reported in patients on antipsychotic treatment, previous studies have not discussed the prognosis of patients with Pisa syndrome. We studied psychiatric patients with Pisa syndrome following antipsychotic treatment for a 2-year period. METHODS: From January 2012 to December 2014, 13 inpatients with Pisa syndrome following antipsychotic treatment were identified at our institution, from a prospectively collected database...
March 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29474194/dextromethorphan-quinidine-in-migraine-prophylaxis-an-open-label-observational-clinical-study
#11
Regina R Berkovich, Alexey Y Sokolov, Daniel M Togasaki, Aida A Yakupova, Paul-Henry Cesar, Soma Sahai-Srivastava
OBJECTIVE: This study aimed to assess potential efficacy and safety of dextromethorphan/quinidine (DMQ) in prophylactic treatment of migraine in patients with multiple sclerosis (MS) with superimposed pseudobulbar affect (PBA). METHODS: Multiple sclerosis patients with superimposed PBA and comorbid migraine were enrolled into this open-label observational study at the University of Southern California Comprehensive MS Center. The baseline characteristics included, among other data, frequency and severity of acute migraine attacks and use of migraine relievers...
March 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29474193/acute-onset-of-abdominal-muscle-dyskinesia-belly-dancer-syndrome-from-quetiapine-exposure-a-case-report
#12
Jia-Yin Yeh, Kun-Yu Tu, Ping-Tao Tseng, Yu Lee, Pao-Yen Lin
Belly dancer syndrome, also called belly dance syndrome or belly dancer dyskinesia, is a kind of abdominal dyskinesia with painful sensation. Its etiology is still unclear and there are few studies reporting its association with antipsychotics. Quetiapine is an atypical antipsychotic that causes lower risk of extrapyramidal symptoms than typical antipsychotics. Here, we presented the first case of belly dancer syndrome in a 71-year-old woman with major depressive disorder after short-term use of quetiapine.
March 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29432287/allergy-to-carbidopa
#13
Mariana Aurora Cansino-Torres, Valeria Sandoval-Rodríguez, Michel Sáenz-Farret, Carlos Zúñiga-Ramírez
BACKGROUND: D-Decarboxylase inhibitors, such as carbidopa or benserazide, have been used as adjunct therapy in Parkinson disease shortly after levodopa synthesis in the 1960s. These compounds increase intracerebral drug concentration and decrease adverse effects by blocking peripheral conversion to dopamine. Skin rash as part of an allergic reaction was previously described in subjects who were using levodopa in combination with carbidopa or benserazide; however, etiology was never clear...
March 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29432286/effect-of-concomitant-medications-on-the-safety-and-efficacy-of-extended-release-carbidopa-levodopa-ipx066-in-patients-with-advanced-parkinson-disease-a-post-hoc-analysis
#14
Peter A LeWitt, Leo Verhagen Metman, Robert Rubens, Sarita Khanna, Sherron Kell, Suneel Gupta
OBJECTIVES: Extended-release (ER) carbidopa-levodopa (CD-LD) (IPX066/RYTARY/NUMIENT) produces improvements in "off" time, "on" time without troublesome dyskinesia, and Unified Parkinson Disease Rating Scale scores compared with immediate-release (IR) CD-LD or IR CD-LD plus entacapone (CLE). Post hoc analyses of 2 ER CD-LD phase 3 trials evaluated whether the efficacy and safety of ER CD-LD relative to the respective active comparators were altered by concomitant medications (dopaminergic agonists, monoamine oxidase B [MAO-B] inhibitors, or amantadine)...
March 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29432285/a-well-tolerated-and-effective-antiepileptic-drug-for-patients-with-myasthenia-gravis-at-last
#15
José Manuel Sánchez-Villalobos, Irene Villegas-Martínez, José Antonio Pérez-Vicente
Antiepileptic drugs have been known to worsen myasthenia gravis (MG) symptoms, and therefore, in patients who suffer both conditions (myasthenia and epilepsy), treatment selection is difficult. We report 2 cases of patients with MG who were safely treated with lacosamide. Evidence about antiepileptic drug treatment and adverse effects in MG is reviewed.
March 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29401068/camptocormia-induced-by-a-dopaminergic-agonist
#16
Tomoo Mano
Camptocormia, a condition that involves the abnormal flexion of the trunk and results in a forward-bending posture, is relatively common during the course of Parkinson disease (PD). Despite this, there is ongoing controversy concerning its mechanisms and no consensus regarding the underlying etiology. This report demonstrates a case in which a dopaminergic agonist (DA) was implicated in the onset of camptocormia episodes in a non-PD patient who developed camptocormia after the start of DA treatment. Over a course of 8 years, the patient experienced intermittent camptocormia, which resulted in multiple falls...
March 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29389745/safety-and-efficacy-of-rituximab-experience-of-a-single-multiple-sclerosis-center
#17
Brett Alldredge, Allison Jordan, Jaime Imitola, Michael K Racke
OBJECTIVES: Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system. B cells play an important pathogenic role in MS. Rituximab (RTX), a B-cell depleting drug, has been used to treat MS and neuromyelitis optica (NMO). Patient characteristics, safety, and efficacy measures are reviewed to ascertain the therapeutic benefit and safety of RTX in a real-world setting with long-term follow-up. METHODS: This is a retrospective chart review of patients who received RTX at The Ohio State University's MS clinic from January 2005 to October 2016...
March 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29303801/intravenous-valproic-acid-add-on-therapy-in-acute-agitation-adolescents-with-suspected-substance-abuse-a-report-of-six-cases
#18
Claudia Battaglia, Roberto Averna, Milena Labonia, Assia Riccioni, Stefano Vicari
The aim of this study was to test efficacy and safety of intravenous (IV) valproate for aggression in children and adolescents with mood or conduct disorder and concomitant substance abuse. Six patients received a 20 mg/kg dose of IV valproic acid as an add-on therapy to their standard therapy with second-generation antipsychotics and benzodiazepines. Agitation and general psychopathology were measured at baseline and after the first injection using the Modified Overt Aggression Scale, the Brief Psychiatric Rating Scale, and the Children's Global Assessment Scale...
January 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29303800/prescribing-trends-of-atypical-antipsychotic-drugs-in-an-outpatient-unit-of-a-child-and-adolescent-clinic-in-turkey
#19
Çiğdem Yektaş, Ali Evren Tufan
OBJECTIVE: Use of antipsychotic agents in the management of various psychopathologies in Child and Adolescent Psychiatric practice is gradually increasing. This study aimed to evaluate the sociodemographic and clinical features of children and adolescents who applied to an outpatient clinic of child and adolescent psychiatry department in Turkey and were prescribed atypical antipsychotics. METHOD: Patients with prescription codes of ATC N05A (except N05AN lithium) were accepted to denote those with atypical antipsychotic treatment...
January 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29303799/open-access-electronic-diary-for-motor-fluctuation-and-dyskinesia-evaluation-in-parkinson-disease-comparison-with-paper-diary
#20
Cinthia Terroba-Chambi, Veronica Bruno, Alex Medina-Escobar, Federico Nanni, Daniel Cerquetti, Malco Rossi, Marcelo Merello
OBJECTIVE: To determine the utility of an electronic diary for registering motor fluctuations and dyskinesia in Parkinson disease (PD). METHODS: Free, open-access touch screen software suitable for Android 4.4 or higher, with medication alarms, adjustable intervals, and medication dose settings was developed to evaluate ON-OFF periods and dyskinesia. Prospective evaluation included a first phase conducted to make adjustments concerning motor limitations when using the tablet, as well as for proper motor complication identification, and a second phase of 3 days of use at home with a prior diary training session comparing a modified paper version of Core Assessment Program for Surgical Interventional Therapies in PD and the electronic diary...
January 2018: Clinical Neuropharmacology
journal
journal
26752
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"